A novel immune-related RNA-binding proteins signature to predict survival and therapeutic responses in prostate cancer

Clin Transl Oncol. 2022 Jul;24(7):1381-1394. doi: 10.1007/s12094-022-02782-2. Epub 2022 Feb 10.

Abstract

Background: The present study aims to identify immune-related RBPs signature to predict prognosis and therapy response in prostate cancer.

Methods: Differentially expressed RBPs were compared and visualized using R packages. Immune-related RBPs were selected by Pearson correlation analysis. The prognostic immune-related RBPs were identified using the Kaplan-Meier method and LASSO regression. A multivariable Cox regression model was used to construct immune-related RBPs signature.

Results: We constructed a prognostic predictive risk model of prostate cancer containing ten immune-related RBP genes. We found that high-risk prostate cancer patients presented poorer prognosis, higher tumor immune cell infiltration, higher rates of genomic alterations, and were more sensitive to targeted and immunotherapy than the low-risk group.

Conclusions: The immune-related RBPs' signature is an independent prognostic marker that could help screen patients with advanced prostate cancer who are better suited for targeted and immunotherapy.

Keywords: Prognosis; Prostate cancer; RNA-binding proteins; Survival; Therapy response.

MeSH terms

  • Humans
  • Immunotherapy
  • Male
  • Prognosis
  • Proportional Hazards Models
  • Prostatic Neoplasms* / genetics
  • Prostatic Neoplasms* / therapy
  • RNA-Binding Proteins / genetics
  • RNA-Binding Proteins / metabolism

Substances

  • RNA-Binding Proteins